Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Madelena Campbell

Nurse Practitioner, Pediatrics Gulfport, MS Nurse Practitioner

NPI 1720368855 CMS profile 10475990

12261 Highway 49, Suite 11, Gulfport, MS 39503

Open in the dashboard

General payments

$6,151

237 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Madelena Campbell of Gulfport, MS is reported in the CMS Open Payments database as having received $6,151 across 237 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,136 47
2024 General $1,559 53
2023 General $1,153 43
2022 General $1,521 54
2021 General $782 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Madelena Campbell
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to Madelena Campbell were reported at $1,136. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year Madelena Campbell Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $782 $60 $23–$142 $132
2022 $1,521 $72 $27–$161 $149
2023 $1,153 $89 $35–$185 $160
2024 $1,559 $93 $34–$199 $164
2025 $1,136 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,481 31 payments
  2. Regeneron Healthcare Solutions, Inc. $1,196 42 payments
  3. Genzyme Corporation $793 30 payments
  4. Genentech USA, Inc. $771 28 payments
  5. GlaxoSmithKline, LLC. $727 54 payments
  6. Grifols USA, LLC $232 12 payments
  7. Aimmune Therapeutics, Inc. $123 2 payments
  8. Novartis Pharmaceuticals Corporation $118 5 payments
  9. Amgen Inc. $111 8 payments
  10. Galderma Laboratories, L.P. $93 1 payment
  11. Other $507 24 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,846 233 payments
  2. Education $305 4 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,463 56 payments
  2. DUPIXENT Inflammation And Immunology $892 30 payments
  3. Xolair $771 28 payments
  4. NUCALA $674 46 payments
  5. TEZSPIRE $553 15 payments
  6. FASENRA $502 9 payments
  7. DUPIXENT Immunology And Inflammation $304 12 payments
  8. Xembify $232 12 payments
  9. AIRSUPRA $129 2 payments
  10. PALFORZIA $123 2 payments
  11. Other $1,046 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

237 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record